In fact, ruxolitinib, a Janus kinase (JAK) inhibitor used in the treatment of GvHD, is thought to exert its function by preventing downstream signaling of different cytokines, including IFN-γ [87]. The gene discussed is IFNG; the disease is graft versus host disease.